Science reports positive preliminary PRIMAvera pivotal results on restoring central vision

Science Corporation/PRIMA retinal implant

Science Corporation announced positive preliminary results from the 38-patient PRIMAvera pivotal trial testing its PRIMA subretinal implant for geographic atrophy, an advanced form of age-related macular degeneration. Patients achieved clinically meaningful vision restoration, with average 23-letter acuity improvement and one patient reaching 59 letters (11.8 lines) of improvement.

• PRIMA system: photovoltaic subretinal implant, specialized glasses with camera, and pocket processor; entirely wireless with zoom feature that enhances image size.
• Average 23 letters (4.6 lines) improvement at 12 months; 10+ letters defines success threshold; previous vision prosthetics could not restore ability to read letter sequences.
• Safety: natural visual acuity remained stable in implant-off state, suggesting no additional deterioration from implantation; trial designed to support European CE mark approval.